Analysis Plan: Study to Measure the Cost of CHAMPUS-Eligible Participants in Southwest Oncology Group NCI Cooperative Program Cancer Clinical Trials 1988-1996: Technical Report No. 1.
Abstract
The National Cancer Institute's Division of Cancer Treatment, Diagnosis, and Centers (DCTDC) has initiated effort to expand clinical trial participation by proposing coverage agreement of NCI clinical trial participants with various third party payers. An agreement was signed with the Department of Defense (DOD) to allow patients who are beneficiaries of TRICAKE/CHAMPUS to participate in, and be reimbursed for, NCI-sponsored clinical cancer treatment trials. This study is a cancer demonstration project pilot study to evaluate the potential cost impact of the NCI/DOD agreement. The initial study phase identified CHAMPUS eligible beneficiaries (CEBs) diagnosed with cancer and enrolled in NCI clinical trials (1988-1996). CEBs treated for cancer of the breast, prostate, colon, lung, leukemia, and lymphoma in phase 2 and 3 adjuvant, advanced/ recurrent disease trials were identified. The second phase of this study will be to determine the cost of the clinical trials by using TRICARE/CHAMPUS claims data from resource utilization of inpatient and outpatient (ambulatory) professional services and institutional costs CEB enrolled in clinical trials will be compared to a non-trial group disease and clinical matched CEB cancer cases.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 1997
- Accession Number
- ADA333467
Entities
People
- Arnold Potosky
- Mary Mccabe
- Sandra L. Schneider
- Scott A. Optenbeerg